An analysis commissioned by Washington, D.C.’s Pharmaceutical Care Management Association (PCMA) recently confirmed that no correlation exists between prices and rebates contrary to claims that drug costs are proportional to consumer rebates and discounts. Read More »
Endo International announced April 12 a $300 million aggregate principal amount of 5.875% senior secured notes which will be due in 2024 at the price of $1000 for each $1000 principal amount, as related to their prior announcement of private offering. Read More »
The U.S. Food and Drug Administration has approved two applications for treatments of hepatitis C in children. Read More »
Allergan PLC and Ironwood Pharmaceuticals Inc. merged forces with the American Gastroenterological Association to raise awareness about bowel health during Irritable Bowel Syndrome Awareness Month. Read More »
The U.S. FDA has issued a letter in response to the New Drug Application for baricitinib, rejecting the application. Read More »
ALK's house dust mite (HDM) sublingual allergy immunotherapy tablet has been approved in 12 European countries, to include availability for adolescent patients. Read More »
Bedside delivery of medications is a practice that is helping patients live more healthily following discharge from hospitals. Read More »
Biogen will present data on its treatments and investigational treatments for people with multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease at the upcoming American Academy of Neurology annual meeting in Boston. Read More »
The American Society of Health-System Professionals recently announced that the United States updated the Common Rule, a federal regulation that supports research involving human subjects. Read More »
McKesson Corp. and Change Healthcare Holdings Inc. have completed their agreement to build a new health care information technology company titled Change Healthcare. Read More »
Genentech, along with the Breast International Group, Breast European Adjuvant Study Team and Frontier Science Foundation, recently reported positive results from the Phase III Aphinity study for combining Perjeta, Herceptin and chemotherapy in treating certain breast cancer patients. Read More »
.jpg)
Pfizer Inc. and nonprofit Population Services International recently announced a $1 million collaboration that will make it easier for people with hypertension in Myanmar and Vietnam to access medicine and treatment. Read More »
Biologics Inc. has been selected by Lexicon Pharmaceuticals to provide limited distribution of the drug Xermelo. Read More »
The American Society of Health-System Professionals recently launched a pharmacy project aimed at training emergency medical services and law enforcement personnel on how to deliver naloxone to opioid-overdosed individuals. Read More »
Bracco Diagnostics, the U.S. subsidiary of Bracco Imaging, has had its Varibar Pudding product approved by the U.S. Food and Drug Administration. Read More »
Amgen recently announced that a planned overall survival (OS) interim analysis of the Phase 3 head-to-head Endeavor trial delivered positive results. Read More »
Incyte Corporation recently announced that it joined with the National Organization for Rare Disorders (NORD), the European Organization for Rare Disease (EURODIS) and more in recognizing Rare Disease Day 2017. Read More »
EMD Serono, the biopharmaceutical business of Merck KGaA and Pfizer Inc., recently announced that the Biologics License Application (BLA) for their avelumab drug was accepted for Priority Review by the U.S. Food and Drug Administration (FDA). Read More »
The American Society of Health-System Professionals (ASHP) recently announced that Michael Cohen, operations officer for the investigations branch of the Department of Health and Human Services (HHS) Office of Inspector General (OIG) in Washington, D.C., believes clinicians need to not just look at opioids but also at non-controlled drugs when trying to understand drug abuse. Read More »
.jpg)
Shire's Vyvanse (lisdexamfetamine dimesylate) CII is now available in a chewable tablet formulation, making it the only Attention-Deficit/Hyperactivity Disorder and Binge Eating Disorder treatment available in five administration options. Read More »
Alerts Sign-up
